Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Novobiocin - Varsity Pharmaceuticals

Next Previous
Drug Profile

Novobiocin - Varsity Pharmaceuticals

Alternative Names: Pol-Theta Inhibitor; VP 006 - Varsity Pharmaceuticals

Latest Information Update: 23 Jan 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dana-Farber Cancer Institute
  • Developer Varsity Pharmaceuticals
  • Class Antibacterials; Antifungals; Antineoplastics
  • Mechanism of Action DNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 18 Jan 2023 National Cancer Institute plans a phase I trial for solid tumours(Metastatic disease, Second-line therapy or greater, Inoperable/Unresectable) in 2023(PO) (NCT05687110)
  • 08 Apr 2022 Pharmacodynamics data from a preclinical studies in Cancer presented at the 113th Annual Meeting of the American Association for Cancer Research (AACR-2022)
  • 10 Feb 2022 Varsity plans first in-patient clinical studies of VP 006, in 2022

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top